Developer docs
API playgroundTry for free, no card

Search company profiles

OliX Pharmaceuticals

Full company profile

uuid0005t1m

Namestring
OliX Pharmaceuticals
Legal namestring
OliX Pharmaceuticals, Inc. (올릭스 주식회사)
Websiteurl
olixpharma.com
Company typeenum
Public
Founded yearint
2010
Descriptiontext

OliX Pharmaceuticals is a clinical-stage Korean biopharmaceutical company developing RNA interference (RNAi) therapeutics built on its proprietary asymmetric siRNA (asiRNA) chemistry and the integrated OASIS platform, which combines asiRNA, cell-penetrating cp-asiRNA, GalNAc-conjugated liver-targeted siRNA, long asiRNA, tripodal siRNA, bulge-structured siRNA, and a dual-targeting OASIS-D format to address the field's core limitations around off-target effects, immune stimulation, and tissue-specific delivery. Founded in 2010 (as BMT, renamed OliX in 2014) and listed on KOSDAQ under ticker 226950 since 2018, the company operates from a Pangyo R&D Center in Seongnam, South Korea, with subsidiaries in San Diego (OliX US Inc. / R&D Lab) and Sydney (OliX AU Pty Ltd) and an mRNA-focused subsidiary (mCureX Therapeutics) at home.

Its pipeline spans dermatology, ophthalmology, metabolic disease, and pulmonary fibrosis: OLX101A (CTGF-targeted, hypertrophic scar, Phase 2a completed in the US), OLX104C (androgen-receptor, androgenetic alopecia, Phase 1b/2a in Australia), OLX301A (MyD88, dry and wet AMD, Phase 1 completed in the US), OLX702A (MASH/obesity, Phase 1 in Australia, globally licensed to Eli Lilly), OLX201A (idiopathic pulmonary fibrosis), and preclinical OLX501A (ALK7, obesity, 2027 IND target). Patented platform technologies are registered across Korea, the US, Europe, Japan, China, and Australia, supporting enforcement against would-be competitors in major markets.

OliX's business model is asset-light and partnership-centric: the company does not sell products directly and instead generates revenue through out-licensing its platform technologies and pipeline candidates to global pharmaceutical partners (notably Eli Lilly for OLX702A cardiometabolic programs worldwide; Hansoh for GalNAc-asiRNA in cardiovascular and metabolic disease across Greater China; and prior deals with Théa for OLX301A/OLX301D and Hugel for OLX101A, both since concluded), supplemented by an emerging consumer-beautics collaboration with L'Oréal spanning hair, skin, and nail applications. Pricing is not publicly disclosed and operates via upfront fees, development and regulatory milestone payments, and royalties on partner sales, with capital formation supported by a KRW 110 billion (~$81M USD) third-party share allotment in June 2026 from BOLD (L'Oréal's CVC) and Weiss Asset Management LP.

Short descriptiontext

OliX Pharmaceuticals is a clinical-stage Korean biopharmaceutical company developing RNA interference (RNAi) therapeutics built on its proprietary asymmetric siRNA (asiRNA) platform for dermatology, ophthalmology, and metabolic disease indications, and licenses its technology and pipeline to global pharmaceutical and cosmetics partners such as Eli Lilly, L'Oréal, and Hansoh Pharma.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSuwon, South Korea
HQ citystring
Suwon
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
RNA interference therapeutics, siRNA drug development, gene silencing technology, clinical-stage biopharmaceuticals, drug licensing partnerships
Industry6 codes
PRIMARYHLAAADAB
siRNA Therapeutics (gene silencing)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAD
RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAE
RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAF
RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
RNA interference therapeutics
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Technology Licensing and Out-licensing
TypeLicensing Royalties
Description

OliX generates revenue by licensing its proprietary RNAi technologies and pipeline candidates to global pharmaceutical companies. This includes upfront payments, milestone payments tied to development and regulatory achievements, and royalty payments based on product sales.

olixpharma.com
2Strategic Investment
TypeOne Time License
Description

The company raises capital through strategic investments from corporate venture capital funds and asset management firms. In June 2026, OliX secured approximately KRW 110 billion (~$81 million USD) through a third-party allotment of newly issued common shares from BOLD (L'Oréal's CVC) and Weiss Asset Management.

pulse2.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1OASIS (OliX Advanced Small Interfering RNA System)
Description

Proprietary RNAi platform technology that enhances gene-silencing efficiency and enables tissue-specific delivery

pulse2.com
+1 more record
Core offering1 text field

OliX Pharmaceuticals develops RNA interference (RNAi) therapeutics built on its proprietary OASIS platform and asymmetric siRNA (asiRNA) chemistry. The company advances a clinical-stage pipeline of siRNA drug candidates targeting indications in dermatology, ophthalmology, metabolic disease, and rare genetic disorders, while also extending its RNAi platform into consumer cosmetics applications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • OLX501A (ALK7 target) demonstrated up to 84% ALK7 mRNA knockdown in non-human primate models
+3 more records
Product overview1 text field

OliX Pharmaceuticals is a clinical-stage biotech company developing RNAi-based therapeutics through its proprietary OASIS platform. The core technology includes asiRNA, cp-asiRNA (self-delivering), and GalNAc-asiRNA platforms for targeted gene silencing. The company pipeline consists of four main clinical candidates: OLX101A (hypertrophic scars), OLX104C (androgenetic alopecia), OLX301A (age-related macular degeneration), and OLX702A (MASH/obesity), with OLX501A (obesity) in preclinical development. The OASIS platform enables tissue-specific delivery for dermal, ophthalmic, and hepatic applications.

Product and service9 records
1OLX101A
CategorysiRNA therapeutic (dermatology / fibrosis)
Description

siRNA therapeutic candidate targeting connective tissue growth factor (CTGF) for the treatment of hypertrophic scars and related fibrotic skin conditions; designed for patients with pathological scarring.

2OLX104C
CategorysiRNA therapeutic (immunology / dermatology)
Description

siRNA-based therapeutic candidate for the treatment of atopic dermatitis, utilizing OASIS-mediated intracellular delivery into keratinocytes.

3OLX301A
CategorysiRNA therapeutic (ophthalmology)
Description

siRNA therapeutic candidate targeting transforming growth factor beta 2 (TGF-β2) for the treatment of subretinal fibrosis, including complications of neovascular age-related macular degeneration.

4OLX702A
CategorysiRNA therapeutic (metabolic disease)
Description

GalNAc-conjugated asiRNA candidate targeting INHBE for the treatment of obesity and metabolic diseases, developed in partnership with Eli Lilly.

5OLX501A
CategorysiRNA therapeutic (rare genetic disease)
Description

Preclinical siRNA therapeutic candidate for Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD) targeting the DUX4 gene using OASIS-D delivery technology.

6OASIS Platform Technology
CategoryRNAi delivery platform technology
Description

Proprietary RNA interference platform technology that enables self-assembly of siRNA strands with improved stability and efficacy, licensed to partners for therapeutic and cosmetic applications.

7cp-asiRNA Platform
CategoryRNAi delivery platform technology
Description

Cell-penetrating asymmetric siRNA platform technology that enables siRNA delivery into target cells without exogenous carriers, applied across dermatology and cosmetic product development.

8asiRNA Platform
CategoryRNAi chemistry platform
Description

Proprietary asymmetric small interfering RNA chemistry platform that improves siRNA specificity and reduces off-target effects, licensed by OliX for therapeutic and partner programs.

9GalNAc-asiRNA Platform
CategoryRNAi delivery platform technology
Description

GalNAc-conjugated asiRNA platform enabling targeted delivery of siRNA therapeutics to liver hepatocytes, supporting metabolic and rare liver disease programs such as OLX702A.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-29
Description

Pipeline collaboration framework agreement for skin, hair, and nail health applications. Combines OliX's RNAi platform with L'Oréal's beauty science expertise. Includes multiple research programs with potential for cosmetics and innovative beauty products. Expanded from initial 2025 collaboration.

Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2026-04-20
Description

MOU for joint development of AI-based siRNA delivery platform. Collaboration to leverage artificial intelligence for optimizing siRNA delivery systems.

Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2026-02-10
Description

Evaluation and option agreement for TfR-targeted BBB shuttle technology combined with OliX's CNS siRNA candidates. Includes exclusive option for worldwide licensing based on research outcomes. Sweden-based biotech specializing in antibody-based BBB delivery.

Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2026-02-04
Description

CNS-focused research collaboration using VECTrans BBB shuttle platform combined with OliX's siRNA. Material Transfer and Evaluation Agreement (MTEA) to assess CNS delivery efficacy, target gene knockdown, and tissue distribution. Evaluates potential for treating CNS diseases with RNAi therapeutics.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-02-01
Description

Global licensing and collaboration agreement for OLX702A (MASH/obesity treatment) and cardiometabolic programs. OliX transferred technology for worldwide development and commercialization. Represents a major strategic partnership with one of the world's largest pharmaceutical companies.

6Hansoh Pharmaceuticals Group Co., Ltd.
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-03-23
Description

License and collaboration agreement for GalNAc-asiRNA platform for cardiovascular and metabolic diseases targeting Greater China. Hansoh exercised option for one additional therapeutic candidate (2023). Represents established partnership with leading Chinese pharmaceutical company.

olixpharma.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-03-23
Description

Out-licensing agreement for OLX301A and OLX301D (dry and wet AMD treatment) for EU, Africa, and Middle East. Originally licensed in 2019; agreement expanded in 2021 for worldwide rights excluding Asia-Pacific. Note: Rights for OLX301A/OLX301D were returned to OliX in 2024.

Strategic tierSupportingTypeTechnology or Integration
Description

Technology introduction agreement for GalNAc technology for liver-targeted siRNA delivery. OliX incorporated this technology into its platform to enable hepatocyte-specific delivery for liver disease therapeutics.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Research collaboration for OLX301A (dry and wet AMD treatment) development. Combines academic research expertise with OliX's RNAi technology platform.

Strategic tierSupportingTypeImplementation/ SI/ Consulting Partner
Description

Contract research organization conducting toxicology studies for OLX301A (dry and wet AMD treatment). Provides nonclinical safety assessment services.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Global leader in RNAi therapeutics with approved siRNA products (Onpattro, Givlaari, Oxlumo, Amvuttra). Directly competes with OliX on GalNAc liver-targeted and extrahepatic siRNA delivery and target disease areas (MASH, cardiometabolic).

TypeDirect peer
Description

Clinical-stage RNAi company with multiple programs across liver, lung, muscle, and CNS using its own TRiM and GalNAc-based delivery platforms. Closely comparable to OliX in extrahepatic siRNA delivery focus and big-pharma partnership model (e.g., Takeda, Amgen).

TypeDirect peer
Description

Clinical-stage RNAi company developing GalNAc-conjugated siRNA for cardiometabolic and rare diseases with a comparable out-licensing/partnership strategy. Directly comparable in target indication space (MASH, cardiovascular) and delivery approach.

TypeDirect peer
Description

Clinical-stage RNA medicines company developing siRNA and mRNA therapeutics for rare diseases, liver disease, and infectious disease. Comparable in modality (siRNA + mRNA) and clinical-stage profile; OliX's mCureX subsidiary also targets mRNA vaccines.

TypeBroad incumbent
Description

Established leader in antisense oligonucleotide (ASO) therapeutics with multiple approved products (Spinraza, Tegsedi, Waylivra). Comparable as a mature RNA-targeting therapeutics company with broad pipeline, but OliX's siRNA modality and partnership focus distinguish it.

TypeBroad incumbent
Description

Acquired Dicerna in 2021 to build an RNAi pipeline targeting MASH, obesity, and cardiometabolic disease — direct overlap with OliX's OLX702A (MASH/obesity) partnered with Eli Lilly. Comparable target disease focus and modality.

TypeEmerging player
Description

Clinical-stage RNA therapeutics company using stereopure oligonucleotide chemistry with CNS and liver programs. Comparable in targeting extrahepatic tissues (CNS) and oligonucleotide-platform innovation, though using ASO/RNA editing rather than siRNA.

TypeEmerging player
Description

Clinical-stage RNAi company developing siRNA therapeutics for oncology and fibrotic diseases with operations in the US and China. Comparable modality (siRNA) and Asia-Pacific presence, with overlapping target disease areas (fibrosis).

TypeEmerging player
Description

Small clinical-stage RNAi therapeutics company focused on immuno-oncology and skin indications using self-delivering RNAi compounds. Comparable in size and modality focus on local/skin RNAi delivery (Intellitile RNAi technology vs. OliX's cp-asiRNA).

TypeEmerging player
Description

Clinical-stage RNAi company developing DNA-directed RNA interference (ddRNAi) therapeutics for oncology and infectious disease, with an ocular program (BBIT) overlapping OliX's ophthalmology focus (OLX301A for AMD).

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

OliX Pharmaceuticals

RNA interference therapeuticsolixpharma.com

OliX Pharmaceuticals is a clinical-stage Korean biopharmaceutical company developing RNA interference (RNAi) therapeutics built on its proprietary asymmetric siRNA (asiRNA) platform for dermatology, ophthalmology, and metabolic disease indications, and licenses its technology and pipeline to global pharmaceutical and cosmetics partners such as Eli Lilly, L'Oréal, and Hansoh Pharma.

What OliX Pharmaceuticals does

OliX Pharmaceuticals is a clinical-stage Korean biopharmaceutical company developing RNA interference (RNAi) therapeutics built on its proprietary asymmetric siRNA (asiRNA) chemistry and the integrated OASIS platform, which combines asiRNA, cell-penetrating cp-asiRNA, GalNAc-conjugated liver-targeted siRNA, long asiRNA, tripodal siRNA, bulge-structured siRNA, and a dual-targeting OASIS-D format to address the field's core limitations around off-target effects, immune stimulation, and tissue-specific delivery. Founded in 2010 (as BMT, renamed OliX in 2014) and listed on KOSDAQ under ticker 226950 since 2018, the company operates from a Pangyo R&D Center in Seongnam, South Korea, with subsidiaries in San Diego (OliX US Inc. / R&D Lab) and Sydney (OliX AU Pty Ltd) and an mRNA-focused subsidiary (mCureX Therapeutics) at home.

Its pipeline spans dermatology, ophthalmology, metabolic disease, and pulmonary fibrosis: OLX101A (CTGF-targeted, hypertrophic scar, Phase 2a completed in the US), OLX104C (androgen-receptor, androgenetic alopecia, Phase 1b/2a in Australia), OLX301A (MyD88, dry and wet AMD, Phase 1 completed in the US), OLX702A (MASH/obesity, Phase 1 in Australia, globally licensed to Eli Lilly), OLX201A (idiopathic pulmonary fibrosis), and preclinical OLX501A (ALK7, obesity, 2027 IND target). Patented platform technologies are registered across Korea, the US, Europe, Japan, China, and Australia, supporting enforcement against would-be competitors in major markets.

OliX's business model is asset-light and partnership-centric: the company does not sell products directly and instead generates revenue through out-licensing its platform technologies and pipeline candidates to global pharmaceutical partners (notably Eli Lilly for OLX702A cardiometabolic programs worldwide; Hansoh for GalNAc-asiRNA in cardiovascular and metabolic disease across Greater China; and prior deals with Théa for OLX301A/OLX301D and Hugel for OLX101A, both since concluded), supplemented by an emerging consumer-beautics collaboration with L'Oréal spanning hair, skin, and nail applications. Pricing is not publicly disclosed and operates via upfront fees, development and regulatory milestone payments, and royalties on partner sales, with capital formation supported by a KRW 110 billion (~$81M USD) third-party share allotment in June 2026 from BOLD (L'Oréal's CVC) and Weiss Asset Management LP.

OliX Pharmaceuticals firmographics

Firmographics
Name
OliX Pharmaceuticals
Legal name
OliX Pharmaceuticals, Inc. (올릭스 주식회사)
Website
https://olixpharma.com
Company type
Public
Founded year
2010
Operating status
Operating
Headcount range
51–100 employees
Short description
OliX Pharmaceuticals is a clinical-stage Korean biopharmaceutical company developing RNA interference (RNAi) therapeutics built on its proprietary asymmetric siRNA (asiRNA) platform for dermatology, ophthalmology, and metabolic disease indications, and licenses its technology and pipeline to global pharmaceutical and cosmetics partners such as Eli Lilly, L'Oréal, and Hansoh Pharma.
Ownership category
akta.pro rank

OliX Pharmaceuticals industry classification

Industry
Product category
RNA interference therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAADAB
siRNA Therapeutics (gene silencing)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAD
RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAE
RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAF
RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • RNA interference therapeutics
  • SiRNA drug development
  • Gene silencing technology
  • Clinical-stage biopharmaceuticals
  • Drug licensing partnerships

Where OliX Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Suwon
HQ country
South Korea
HQ region
Asia

Offices3 records

Markets served

OliX Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Technology Licensing and Out-licensing: OliX generates revenue by licensing its proprietary RNAi technologies and pipeline candidates to global pharmaceutical companies. This includes upfront payments, milestone payments tied to development and regulatory achievements, and royalty payments based on product sales.
  2. Strategic Investment: The company raises capital through strategic investments from corporate venture capital funds and asset management firms. In June 2026, OliX secured approximately KRW 110 billion (~$81 million USD) through a third-party allotment of newly issued common shares from BOLD (L'Oréal's CVC) and Weiss Asset Management.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

OliX Pharmaceuticals product offering

Product offering

Core offering

OliX Pharmaceuticals develops RNA interference (RNAi) therapeutics built on its proprietary OASIS platform and asymmetric siRNA (asiRNA) chemistry. The company advances a clinical-stage pipeline of siRNA drug candidates targeting indications in dermatology, ophthalmology, metabolic disease, and rare genetic disorders, while also extending its RNAi platform into consumer cosmetics applications.

Product overview

OliX Pharmaceuticals is a clinical-stage biotech company developing RNAi-based therapeutics through its proprietary OASIS platform. The core technology includes asiRNA, cp-asiRNA (self-delivering), and GalNAc-asiRNA platforms for targeted gene silencing. The company pipeline consists of four main clinical candidates: OLX101A (hypertrophic scars), OLX104C (androgenetic alopecia), OLX301A (age-related macular degeneration), and OLX702A (MASH/obesity), with OLX501A (obesity) in preclinical development. The OASIS platform enables tissue-specific delivery for dermal, ophthalmic, and hepatic applications.

Differentiator

Problem solved

Functional benefit

Brands

  • OASIS (OliX Advanced Small Interfering RNA System): Proprietary RNAi platform technology that enhances gene-silencing efficiency and enables tissue-specific delivery
  • mCureX Therapeutics

Products and services

  • OLX101A siRNA therapeutic candidate targeting connective tissue growth factor (CTGF) for the treatment of hypertrophic scars and related fibrotic skin conditions; designed for patients with pathological scarring.
  • OLX104C siRNA-based therapeutic candidate for the treatment of atopic dermatitis, utilizing OASIS-mediated intracellular delivery into keratinocytes.
  • OLX301A siRNA therapeutic candidate targeting transforming growth factor beta 2 (TGF-β2) for the treatment of subretinal fibrosis, including complications of neovascular age-related macular degeneration.
  • OLX702A GalNAc-conjugated asiRNA candidate targeting INHBE for the treatment of obesity and metabolic diseases, developed in partnership with Eli Lilly.
  • OLX501A Preclinical siRNA therapeutic candidate for Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD) targeting the DUX4 gene using OASIS-D delivery technology.
  • OASIS Platform Technology Proprietary RNA interference platform technology that enables self-assembly of siRNA strands with improved stability and efficacy, licensed to partners for therapeutic and cosmetic applications.
  • cp-asiRNA Platform Cell-penetrating asymmetric siRNA platform technology that enables siRNA delivery into target cells without exogenous carriers, applied across dermatology and cosmetic product development.
  • asiRNA Platform Proprietary asymmetric small interfering RNA chemistry platform that improves siRNA specificity and reduces off-target effects, licensed by OliX for therapeutic and partner programs.
  • GalNAc-asiRNA Platform GalNAc-conjugated asiRNA platform enabling targeted delivery of siRNA therapeutics to liver hepatocytes, supporting metabolic and rare liver disease programs such as OLX702A.

Quantifiable outcome

  • OLX501A (ALK7 target) demonstrated up to 84% ALK7 mRNA knockdown in non-human primate models
  • +3 more outcomes

Companies that use OliX Pharmaceuticals

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles2 records

OliX Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature8 records

OliX Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core, supporting and strategic.

  • L'Oréal GroupecoreStrategic or Co-development Partner · 29 June 2026Pipeline collaboration framework agreement for skin, hair, and nail health applications. Combines OliX's RNAi platform with L'Oréal's beauty science expertise. Includes multiple research programs with potential for cosmetics and innovative beauty products. Expanded from initial 2025 collaboration.
  • GaluxesupportingTechnology or Integration · 20 April 2026MOU for joint development of AI-based siRNA delivery platform. Collaboration to leverage artificial intelligence for optimizing siRNA delivery systems.
  • Key2Brain ABstrategicTechnology or Integration · 10 February 2026Evaluation and option agreement for TfR-targeted BBB shuttle technology combined with OliX's CNS siRNA candidates. Includes exclusive option for worldwide licensing based on research outcomes. Sweden-based biotech specializing in antibody-based BBB delivery.
  • Vect-HorusstrategicTechnology or Integration · 4 February 2026CNS-focused research collaboration using VECTrans BBB shuttle platform combined with OliX's siRNA. Material Transfer and Evaluation Agreement (MTEA) to assess CNS delivery efficacy, target gene knockdown, and tissue distribution. Evaluates potential for treating CNS diseases with RNAi therapeutics.
  • Eli Lilly and CompanycoreStrategic or Co-development Partner · 1 February 2025Global licensing and collaboration agreement for OLX702A (MASH/obesity treatment) and cardiometabolic programs. OliX transferred technology for worldwide development and commercialization. Represents a major strategic partnership with one of the world's largest pharmaceutical companies.
  • Hansoh Pharmaceuticals Group Co., Ltd.coreStrategic or Co-development Partner · 23 March 2021License and collaboration agreement for GalNAc-asiRNA platform for cardiovascular and metabolic diseases targeting Greater China. Hansoh exercised option for one additional therapeutic candidate (2023). Represents established partnership with leading Chinese pharmaceutical company.
  • ThéacoreStrategic or Co-development Partner · 23 March 2019Out-licensing agreement for OLX301A and OLX301D (dry and wet AMD treatment) for EU, Africa, and Middle East. Originally licensed in 2019; agreement expanded in 2021 for worldwide rights excluding Asia-Pacific. Note: Rights for OLX301A/OLX301D were returned to OliX in 2024.
  • AM Chemicals LLCsupportingTechnology or IntegrationTechnology introduction agreement for GalNAc technology for liver-targeted siRNA delivery. OliX incorporated this technology into its platform to enable hepatocyte-specific delivery for liver disease therapeutics.
  • University of Virginia School of MedicinesupportingStrategic or Co-development PartnerResearch collaboration for OLX301A (dry and wet AMD treatment) development. Combines academic research expertise with OliX's RNAi technology platform.
  • Charles River LaboratoriessupportingImplementation/ SI/ Consulting PartnerContract research organization conducting toxicology studies for OLX301A (dry and wet AMD treatment). Provides nonclinical safety assessment services.

Scale indicators4 records

Recent moves7 records

Expansion highlights7 records

OliX Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Alnylam Pharmaceuticals: Global leader in RNAi therapeutics with approved siRNA products (Onpattro, Givlaari, Oxlumo, Amvuttra). Directly competes with OliX on GalNAc liver-targeted and extrahepatic siRNA delivery and target disease areas (MASH, cardiometabolic).
  • Arrowhead Pharmaceuticals: Clinical-stage RNAi company with multiple programs across liver, lung, muscle, and CNS using its own TRiM and GalNAc-based delivery platforms. Closely comparable to OliX in extrahepatic siRNA delivery focus and big-pharma partnership model (e.g., Takeda, Amgen).
  • Silence Therapeutics: Clinical-stage RNAi company developing GalNAc-conjugated siRNA for cardiometabolic and rare diseases with a comparable out-licensing/partnership strategy. Directly comparable in target indication space (MASH, cardiovascular) and delivery approach.
  • Arcturus Therapeutics: Clinical-stage RNA medicines company developing siRNA and mRNA therapeutics for rare diseases, liver disease, and infectious disease. Comparable in modality (siRNA + mRNA) and clinical-stage profile; OliX's mCureX subsidiary also targets mRNA vaccines.

Broad incumbents

  • Ionis Pharmaceuticals: Established leader in antisense oligonucleotide (ASO) therapeutics with multiple approved products (Spinraza, Tegsedi, Waylivra). Comparable as a mature RNA-targeting therapeutics company with broad pipeline, but OliX's siRNA modality and partnership focus distinguish it.
  • Novo Nordisk (Dicerna): Acquired Dicerna in 2021 to build an RNAi pipeline targeting MASH, obesity, and cardiometabolic disease — direct overlap with OliX's OLX702A (MASH/obesity) partnered with Eli Lilly. Comparable target disease focus and modality.

Emerging players

  • Wave Life Sciences: Clinical-stage RNA therapeutics company using stereopure oligonucleotide chemistry with CNS and liver programs. Comparable in targeting extrahepatic tissues (CNS) and oligonucleotide-platform innovation, though using ASO/RNA editing rather than siRNA.
  • Sirnaomics: Clinical-stage RNAi company developing siRNA therapeutics for oncology and fibrotic diseases with operations in the US and China. Comparable modality (siRNA) and Asia-Pacific presence, with overlapping target disease areas (fibrosis).
  • Phio Pharmaceuticals: Small clinical-stage RNAi therapeutics company focused on immuno-oncology and skin indications using self-delivering RNAi compounds. Comparable in size and modality focus on local/skin RNAi delivery (Intellitile RNAi technology vs. OliX's cp-asiRNA).
  • Benitec Biopharma: Clinical-stage RNAi company developing DNA-directed RNA interference (ddRNAi) therapeutics for oncology and infectious disease, with an ocular program (BBIT) overlapping OliX's ophthalmology focus (OLX301A for AMD).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

OliX Pharmaceuticals social profiles

Digital presence

OliX Pharmaceuticals compliance and trust

Trust signal

Compliance1 record

OliX Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

OliX Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles6 records

OliX Pharmaceuticals subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

OliX Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

OliX Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OliX Pharmaceuticals

What does OliX Pharmaceuticals do?

OliX Pharmaceuticals develops RNA interference (RNAi) therapeutics built on its proprietary OASIS platform and asymmetric siRNA (asiRNA) chemistry. The company advances a clinical-stage pipeline of siRNA drug candidates targeting indications in dermatology, ophthalmology, metabolic disease, and rare genetic disorders, while also extending its RNAi platform into consumer cosmetics applications.

Is OliX Pharmaceuticals a public or private company?

OliX Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was OliX Pharmaceuticals founded?

OliX Pharmaceuticals was founded in 2010. It employs 51 to 100 people.

Where is OliX Pharmaceuticals based?

OliX Pharmaceuticals is headquartered in Suwon, South Korea, in the Asia region.

How does OliX Pharmaceuticals make money?

Two revenue lines are on record. Technology Licensing and Out-licensing is the primary driver. The others are strategic Investment.

Who are OliX Pharmaceuticals's main competitors?

Direct peers on record are Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Silence Therapeutics and Arcturus Therapeutics. Broad incumbents are Ionis Pharmaceuticals and Novo Nordisk (Dicerna). Emerging players are Wave Life Sciences, Sirnaomics, Phio Pharmaceuticals and Benitec Biopharma.

Does OliX Pharmaceuticals have an API?

No public API is recorded for OliX Pharmaceuticals.

What industry is OliX Pharmaceuticals in?

OliX Pharmaceuticals's product category is RNA interference therapeutics. Its primary akta.pro industry code is HLAAADAB, siRNA Therapeutics (gene silencing), with a secondary code of HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BitgetOliX Says New Zealand Ethics Panel Approves OLX10212 Phase 2a Trial After ReviewOliX Pharmaceuticals' New Zealand ethics panel approved its Phase 2a trial of OLX10212 for age-related macular degeneration after a reconsideration. The trial targets bilateral geographic atrophy, and MedSafe approval is still required, with the company to disclose that decision.NateOliX Slides…What's Next for OLX301A?[K-Bio Pulse] : 네이트 뉴스OliX Pharmaceuticals fell 5.72% to 90,600 won after resubmitting its New Zealand trial application for OLX301A, an siRNA candidate for macular degeneration. The application was rejected over administrative matters requiring additional documentation. OliX awaits another ethics decision and the clinical study report for OLX702A.NaverOliX Slides…What’s Next for OLX301A?[K-Bio Pulse]OliX Pharmaceuticals' stock fell 5.72% to 90,600 won after its New Zealand trial application for OLX301A was rejected over administrative issues, though the company resubmitted it. The siRNA candidate for macular degeneration awaits ethics approval, while the company also expects a clinical study report for OLX702A by year-end.NaverLemon Hits Limit-Up; Licensing Hopes Lift G2G, OliX[K-Bio Pulse]South Korean biotech stocks rose on October 21, with Lemon Healthcare hitting the daily limit up 29.88% and G2G Bio up 14.46% on potential Novo Nordisk licensing. OliX gained 9.73% after its CEO said licensing talks had advanced. No specific licensing deals were confirmed.The future of tradingOliX Pharmaceuticals to host in-person investor relations briefing for individual shareholdersOliX Pharmaceuticals will hold an in-person investor relations briefing for individual shareholders on Oct. 19, 2026, from 10:00 a.m. to 11:00 a.m. local time at its Seongnam, Gyeonggi Province offices. Management plans to brief on R&D progress and business updates, then take questions.Nate'Different from existing treatments'… K-pharmaceuticals seeking new hair loss medication: Nate NewsKorean pharmaceutical and bio companies JW Pharmaceutical, Olix, and GAI Innovation are developing new hair loss drugs using novel mechanisms that differ from existing DHT-suppressing treatments, which have been associated with side effects such as decreased libido and depression. JW Pharmaceutical has received IND approval for its first-in-class candidate JW0061, which directly binds to the GFRA1 receptor of hair follicle stem cells to induce hair growth, while Olix has completed Phase 1b dosing for its RNA interference-based treatment OLX104C in Australia. GAI Innovation's affiliate GAI Longgevity has registered its triple fusion protein GL-SRF-007 in the INCI database as a hair loss treatment candidate targeting dormant hair follicle stem cells through BMP signal regulation.YahooOliX’s OLX501A Demonstrates Greater Visceral Fat Reduction Relative to a Global Comparator in Obese Non-Human PrimatesOliX Pharmaceuticals announced preclinical data from a head-to-head study in obese non-human primates showing that its ALK7-targeting OLX501A achieved 29.2% visceral fat reduction at Day 49, compared to 10.0% for a globally developed comparator and an 11.1% increase in the control group. The study administered both compounds subcutaneously at 3 mg/kg with two doses one month apart, with MRI analysis confirming the differentiated effect despite generally comparable target engagement. The company indicated the findings may support future partnering and out-licensing discussions for the RNAi-based obesity therapy.Global Cosmetics NewsL’Oréal expands RNAi research partnership with OliX into nail healthL'Oréal expanded its RNAi research partnership with South Korean biotech OliX to include nail health, building on a 2025 collaboration. The companies will jointly develop cosmetic solutions for hair, skin, and nails, with OliX leading discovery and L'Oréal providing funding. The move follows L'Oréal's BOLD fund's KRW10.5 billion investment in OliX.36krL'Oréal Invests 10 Million in 100-Billion-Yuan TrackL'Oréal Group's venture capital fund BOLD invested approximately 1.05 billion won (around 46.55 million yuan) in South Korean RNA technology company OliX Pharmaceuticals through a private placement that raised roughly 110 billion won total. The investment deepens an existing R&D partnership formed in June 2025, where OliX leads development using its asymmetric siRNA platform for hair-loss treatments while L'Oréal provides product development and commercialization guidance. The deal reflects L'Oréal's strategic push into the anti-hair-loss market, which is projected to exceed $10 billion globally by 2029, as the world's largest beauty company seeks to apply gene-level technology to hair-care products.Global Cosmetics NewsOliX Pharmaceuticals secures KRW 110 billion investment from L’Oréal venture fund and Weiss Asset ManagementOliX Pharmaceuticals has raised approximately KRW 110 billion through a strategic investment from BOLD, L'Oréal's corporate venture capital fund, and U.S.-based Weiss Asset Management via a third-party allotment of newly issued common shares. The South Korean biotechnology company plans to use the proceeds to advance its RNA interference (RNAi) therapeutic pipeline focused on skin and hair applications. The investment deepens OliX's existing strategic partnership with L'Oréal, combining its siRNA platform with L'Oréal's biology, formulation science, and beauty innovation expertise to accelerate next-generation beauty and wellness solutions.